ReviewCureus2018
Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country-Nepal: Cost, Efficacy, and Safety.
Review in Cureus, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06498323 (Intravenous Tenecteplase Versus Alteplase for Acute Ischemic Stroke Treatment on Mobile Stroke Units, a Prospective Multicenter Randomized Controlled Trial), which is not on this map. Cited by 20 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intravenous Tenecteplase Versus Alteplase for Acute Ischemic Stroke Treatment on Mobile Stroke Units, a Prospective Multicenter Randomized Controlled Trial
Who cites it
20 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Tenecteplase versus alteplase in bridging therapy in patients with large vessel occlusion stroke: a meta-analysis.Frontiers in neurology · 2025Pooled it
- Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials.Annals of medicine · 2024Pooled it
- Tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis of randomized and non-randomized studies.Journal of neurology · 2024Pooled it
- Tenecteplase vs. alteplase for the treatment of patients with acute ischemic stroke: a systematic review and meta-analysis.Journal of neurology · 2022Pooled it
- Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Tenecteplase thrombolytic therapy for acute ischaemic stroke in China: a real-world, multicentre, retrospective, controlled study.Stroke and vascular neurology · 2025Article
- Updates in Intravenous Thrombolysis Treatment for Acute Ischemic Stroke in Asian Populations.Aging and disease · 2025Review
- Thrombolysis for acute ischaemic stroke: development and update.Brain communications · 2025Review
- Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Systematic Review and Meta-analysis.Annals of neurosciences · 2024Review
- Tenecteplase for Acute Ischemic Stroke Thrombolysis: Practical Considerations and Real-World Implementation.Neurology. Clinical practice · 2024Article
- Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.Neurology and therapy · 2023Review
- Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke.European stroke journal · 2023Article
- Feasibility of switching from alteplase to tenecteplase for stroke thrombolysis - A retrospective cohort analysis.IBRO neuroscience reports · 2023Article
- European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke.European stroke journal · 2023Article
- An opportunity to improve Acute Ischemic Stroke care in the South Asian region through telestroke services.Annals of medicine and surgery (2012) · 2021Article
- Early Hospital Arrival After Acute Ischemic Stroke Is Associated With Family Members' Knowledge About Stroke.Frontiers in neurology · 2021Article
- Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?The western journal of emergency medicine · 2020Review
- Long noncoding RNA NEAT1 correlates with higher disease risk, worse disease condition, decreased miR-124 and miR-125a and predicts poor recurrence-free survival of acute ischemic stroke.Journal of clinical laboratory analysis · 2020Article
- Status of prehospital delay and intravenous thrombolysis in the management of acute ischemic stroke in Nepal.BMC neurology · 2019Article
- Tenecteplase and Alteplase for Thrombolysis of Acute Ischemic Stroke within 4.5 Hours: An Efficacy and Safety Study.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered, mutant tissue plasminogen activator, is an alternative thrombolytic agent. The economic feasibility of stroke treatment has been a matter of huge debate and discussion thus far. The use of thrombolytics for the management of ischemic stroke has recently begun in Nepal. In low-income countries like Nepal, where the per capita income falls at just $691.7 and 25.2% of the population are under the poverty line, stroke patients cannot meet treatment expenses. Tenecteplase is easily available (for the management of acute coronary syndrome) in tertiary-level hospitals of Nepal and the price quote of tenecteplase ($450) is half the price of alteplase ($1000). In emergency cases, sometimes, the cost of alteplase can be greater than the patient can afford and they can't undergo thrombolysis even after arriving on time. However, evidence exists that supports the use of other alternatives (tenecteplase), which are also effective in the management of acute ischemic stroke. In this article, we examined current evidence for the efficacy and safety of tenecteplase when compared to alteplase. This review will make neurologists in Nepal familiar with the efficacy and safety of tenecteplase in comparison with alteplase since it is common for patients to not be able to afford the expensive alteplase, which makes guideline-based practice impossible some times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.